IP Library › Granted Patent US 12,642,876
Granted Patent B1
US 12,642,876 · App. 19/375,067 · Granted Jun 2, 2026

Cholecystokinin-2 receptor targeted compounds and use thereof

Inventors: Dijie Liu (Iowa City, IA); Mengshi Li (Iowa City, IA); Nicholas Baumhover (Iowa City, IA); M M Hasibuzzaman (Iowa City, IA); Dulanjali Thennakoon (Iowa City, IA); Zhiming Dai (Iowa City, IA); Michael K. Schultz (Iowa City, IA)
Assignee: Perspective Therapeutics, Inc.
A61K51/088A61K2121/00A61K2123/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,876
App. No.
19/375,067
Granted
Jun 2, 2026
Kind
B1
Abstract

The present disclosure provides, inter alia, novel compounds targeting cholecystokinin-2 receptor (CCK2R) expressed on the surface of cancer cells. Also provided are methods for imaging, diagnosing, and/or treating cancers using the same.

Claims (11)

1 . A peptidomimetic conjugate having a structure selected from one of the following:

2 . The peptidomimetic conjugate according to claim 1 , wherein the peptidomimetic conjugate is capable of chelating a radionuclide.

3 . The peptidomimetic conjugate according to claim 2 , wherein the radionuclide is 203 Pb or 212 Pb.

4 . The peptidomimetic conjugate according to claim 2 , wherein the radionuclide is 61 Cu, 64 Cu, 67 Cu, or 68 Ga.

5 . A method for imaging or diagnosing a subject suffering from a cancer associated with expression of cholecystokinin-2 receptor (CCK2R), the method comprising administering the peptidomimetic conjugate of claim 1 to the subject, wherein the peptidomimetic conjugate is complexed with a radionuclide suitable for medical imaging use, and imaging the subject.

6 . A method for treating a subject suffering from a cancer associated with expression of CCK2R, the method comprising administering the peptidomimetic conjugate of claim 1 to the subject, wherein the peptidomimetic conjugate is complexed with a radionuclide suitable for therapeutic use, in a dosage sufficient to kill cancer cells.

7 . A method of diagnosing and treating a subject suffering from a cancer associated with expression of CCK2R, the method comprising:

diagnosing the subject by administering the peptidomimetic conjugate of claim 1 to the subject, wherein the peptidomimetic conjugate is complexed with a radionuclide suitable for medical imaging use, and imaging the subject to diagnose the subject as being afflicted with the cancer, and

treating the subject diagnosed as being afflicted by the cancer, by administering the peptidomimetic conjugate of claim 1 to the subject, wherein the peptidomimetic conjugate is complexed with a radionuclide suitable for therapeutic use, in a dosage sufficient to kill cancer cells.

8 . The method according to claim 5 , wherein the subject is imaged using single-photon emission computed tomography (SPECT) imaging or positron emission tomography (PET), optionally in combination with computed tomography (CT) imaging.

9 . The method according to claim 7 , wherein the cancer associated with expression of CCK2R is selected from thyroid cancer, lung cancer, tumors of the nervous system, ovarian cancer, gastrointestinal cancer, neuroendocrine tumors, neuroblastoma, endometrial cancer, insulinomas, prostate cancer, breast cancer, vipomas, bronchial carcinoids, ileal carcinoids, and sarcomas.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2025
From: LIU, DIJIE; LI, MENGSHI; BAUMHOVER, NICHOLAS; HASIBUZZAMAN, M M; THENNAKOON, DULANJALI; DAI, ZHIMING; SCHULTZ, MICHAEL K.
To: PERSPECTIVE THERAPEUTICS, INC.
Reel/Frame 073191/0455 →
References Cited (30)
US 10874753B2 · Driver et al. · 2020 [cited by applicant]
US 11344623B2 · Low et al. · 2022 [cited by applicant]
US 11623014B2 · Behe et al. · 2023 [cited by applicant]
US 11826436B2 · Blower et al. · 2023 [cited by applicant]
US 12049518B2 · Von Guggenberg Zu Riedhofen et al. · 2024 [cited by applicant]
US 12358966B2 · Ostertag et al. · 2025 [cited by applicant]
US 12427209B2 · Perrin et al. · 2025 [cited by applicant]
US 20220401592A1 · Pomper et al. · 2022 [cited by applicant]
US 20240091390A1 · Von Guggenberg Zu Riedhofen et al. · 2024 [cited by applicant]
WO 2023173174A1 · 2023 [cited by applicant]
WO 2023191839A2 · 2023 [cited by applicant]
WO 2023201435A1 · 2023 [cited by applicant]
WO 2024061483A1 · 2024 [cited by applicant]
Dillemuth et al. Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules. EJNMMI radiopharm. chem. 10, 40 (2025). [cited by applicant]
Berge et al. Pharmaceutical salts. J Pharm Sci. Jan. 1977;66(1):1-19. doi: 10.1002/jps.2600660104. PMID: 833720. [cited by applicant]
Remington—The Science and Practice of Pharmacy, 21st edition (Gennaro et al editors. Lippincott Williams & Wilkins Philadelphia). [cited by applicant]
Maina et al. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients, … [cited by applicant]
Lipiński et al. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor. EJNMMI Res 8, 33 (2018). [cited by applicant]
Li, M., et al., Automated cassette-based production of high specific activity [(203/212)Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot, 2017. 127: p.… [cited by applicant]
Klingler, M., et al., DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med, 2019. 60(7): p. 1010-1016. [cited by applicant]
Lee, D., et al., Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. Eur J Nucl Med Mol Imaging, 2024. 51(4): p. … [cited by applicant]
Li, M., et al., Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for (203)Pb and (212)Pb-Based Theranostics. Pharmaceutics, 2023. 15(2). [cited by applicant]
Ocak, M., et al., Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under Cost BM0607. Eur J Nucl Med Mol Imaging, 2011. 38(8): p. 1426-35. [cited by applicant]
Günther, T., et al., Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer. J Nucl Med, 2024. 65(1): p. 33-39. [cited by applicant]
Viering, O., et al., Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer. Clin Nucl Med, 2024. 49(12): p. 1091-1097. [cited by applicant]
Holzleitner, N., et al., Preclinical evaluation of (225)Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy. Eur J Nucl Med Mol Imaging, 2025. 52(2): p. 458-468. [cited by applicant]
Sauter AW et al. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J Nucl Med 2019; 60:393-399. [cited by applicant]
Viering O. et al. CCK2 Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga]Ga-DOTA-CCK-66. J Nucl Med. Mar. 1, 2024;65(3):493-494. [cited by applicant]
Lezaic L. et al. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical… [cited by applicant]
Rottenburger et al. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J Nucl Med. Apr. 2020;61(4):520-526. [cited by applicant]